Results 121 to 130 of about 275,402 (290)

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients

, 2007
BACKGROUND: It is unclear whether new treatment modalities have improved the survival of follicular lymphoma patients. Some data show that there has been no improvement in survival in the last 3 decades of the 20th century, whereas the results of recent ...
D. Vallisa, S. Sacchi, SACCHI, Stefano, MARCHESELLI, Luigi, F. Merli, S. Luminari, POZZI, Samantha, BARI, Alessia, F. Angrilli, L. Baldini, LUMINARI, Stefano, S. Pozzi, M. Brugiatelli, I. L. Study Group, L. Marcheselli, A. Bari, Italian lymphoma study group   +16 more
core   +1 more source

Real‐World Safety and Efficacy of Pola‐R‐CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients

Cancer Science, EarlyView.
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode, Hitomi Sawa, Kohta Miyawaki, Atsushi Satake, Nobuhiro Kanemura, Ritsuro Suzuki, Yuki Fujiwara, Yasuhiro Nagate, Shuichi Ota, Takahiro Fujino, Hideki Goto, Noriko Fukuhara, Mamiko Sakata‐Yanagimoto, Koji Izutsu, Momoko Nishikori, Hirohiko Shibayama, Daisuke Ennishi, Takayuki Shimose, Mai Asai, Itaru Matsumura, Koichi Akashi, Koji Kato   +21 more
wiley   +1 more source

Molecular pathophysiology of indolent lymphoma

Haematologica, 2000
Indolent lymphomas are a markedly heterogeneous group of lymphoproliferative disorders including B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, lymphoplasmacytoid lymphoma, follicular lymphoma, mantle cell lymphoma and mucosa-associated ...
D Capello, G Gaidano
doaj  

Neoplasias de células linfoides maduras B: avaliação dos casos diagnosticados e acompanhados no hospital universitário da Universidade Federal de Santa Catarina entre 2011 e 2014 [PDF]

, 2015
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde, Programa de Pós-Graduação em Farmácia, Florianópolis, 2015.De acordo com a classificação da OMS (2008), as neoplasias de células maduras B (NCLM-B) abrangem os ...
Cardoso, Chandra Chiappin
core  

and Risk of Follicular Lymphoma

, 2006
The reasons for the positive association between skin cancer and non-Hodgkin's lymphoma are not known but may be due to common susceptibility involving suboptimal DNA repair.
Schöllkopf, Claudia, Adami, Hans Olov, Claudia Schöllkopf, Hjalgrim, Henrik, Palmgren, Juni, Juha Kere, Glimelius, Bengt,, Hans-Olov Adami, Mads Melbye, Kere, Juha, Adami, Hans-Olov, Lindgren, Cecilia M., Humphreys, Keith, Chang, Ellen T., Ryder, Lars P., Melbye, Mads, Cecilia M. Lindgren, Henrik Hjalgrim, Roos, Göran, Falk, Kerstin I., Glimelius, Bengt, Keith Humphreys, Karin Ekström Smedby, Ellen T. Chang, Göran Roos, Kerstin I. Falk, Juni Palmgren, Smedby, Karin Ekström, Lars P. Ryder, Bengt Glimelius   +29 more
core   +1 more source

Aberrant Expression of Multiple T‐Cell Markers in Primary Cutaneous Follicle Center Lymphoma: A Rare Case Report

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Aberrant expression of T‐cell markers in B‐cell lymphomas is rare and can pose diagnostic challenges. We report a case of a 65‐year‐old man presenting with newly developed scalp nodules. Histopathology revealed nodular lymphoid infiltrates composed of large centrocytes and centroblasts.
V. Pfefferle, A. Vogelsberg, M. Maaß, C. M. Schürch, S. Forchhammer   +4 more
wiley   +1 more source

Transformation of follicular lymphoma [PDF]

American Journal of Hematology, 2018
Wenchee, Siow, Kieran, Burton, Helen, Eagleton, Carolyn, Campbell, Barbara J, Bain   +4 more
openaire   +2 more sources

Consensus‐based Guideline on tinea capitis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The consensus‐based guideline developed under the auspices of the German Dermatological Society (DDG) is intended to provide physicians with a structured framework for clinical decision‐making in the management of patients with tinea capitis and to contribute to improved diagnostic accuracy, treatment adherence, and prevention. Tinea capitis is
Peter Mayser, Dietrich Abeck, Philipp P. Bosshard, Jochen Brasch, Georg Daeschlein, Isaak Effendy, Yvonne Gräser, Peter Höger, Julia Huynh, Maria Kinberger, Annette Kolb‐Mäurer, Katharina Antonia Langen, Bartosz Malisiewicz, Alexander Nast, Hagen Ott, Christin Pelzer, Dieter Reinel, Martin Schaller, Silke Uhrlaß, Pietro Nenoff   +19 more
wiley   +1 more source